RS Oncology Data for Novel Treatment of Aggressive Cancers Selected for an Oral Presentation at ASCO Annual Meeting
May 01 2024 - 7:18AM
Business Wire
- Data from phase 1 clinical trial of RSO-021 selected for the
Developmental Therapeutics session on June 3rd, 2024
- Trial in progress for the ongoing expansion cohorts will be
presented as a poster in the Lung Cancer session on June 3rd,
2024
RS Oncology, a clinical-stage biopharmaceutical company focused
on developing novel treatments for aggressive and rare cancers,
today announced that it will present the complete Phase 1 dose
escalation data as an oral presentation at the world’s largest
oncology meeting, the 2024 American Society of Clinical Oncology
(ASCO) Annual Meeting.
The MITOPE phase 1 multicenter study, (clinical trials.gov
#NCT05278975) investigating the safety and tolerability of RSO-021,
is a first-in-human trial. RSO-021 is a first-in-class therapy for
treatment of mesothelioma and solid tumors in patients with
malignant pleural effusion. Professor Dean Fennell from Leicester
Hospitals Trust in the UK will present the complete dose escalation
data as part of a rapid oral session and answer questions during a
moderated panel discussion.
Aggressive cancers present tremendous challenges in treatment
and management, primarily due to rapid growth and spread to other
parts of the body. Malignant pleural effusion (MPE) develops as a
direct extension of cancer into the pleural space and is associated
with shorter life expectancies. Currently, the phase 2 expansion
portion of MITOPE is underway in the UK, exploring RSO-021 as both
a single agent and in combination therapy to treat stage IV
metastatic cancers with MPE, including mesothelioma, lung, breast
and ovarian cancers. Other causes of MPE include cancer that has
spread from the stomach, kidney, ovaries, and colon. Dr. Sean
Dulloo from University of Leicester will present an update of the
MITOPE Phase 2 trial as a trial-in-progress poster
presentation.
The data is embargoed until published by ASCO 5:00 PM (EDT) on
Thursday, May 23, 2024.
Details of the Presentations
Rapid Oral Abstract Title: First-in-human phase 1
clinical trial of RSO-021, a first-in-class covalent inhibitor of
mitochondrial peroxiredoxin 3 (PRX3), in patients with malignant
pleural effusion due to mesothelioma and other advanced solid
tumors (MITOPE). Presenter: Dean Fennell Session
Title: Developmental Therapeutics—Molecularly Targeted Agents
and Tumor Biology Day/Time: Monday, June 3, 9:06 am (session
from 8:00-9:30 am) Abstract #3019
Poster Presentation Title: Phase 2 study to evaluate the
novel mitochondrial PRX3 inhibitor, RSO-021, as an intrapleural
monotherapy and in combination with IV paclitaxel in patients with
malignant pleural effusion due to mesothelioma or another advanced
solid tumor. Presenter: Sean Dulloo Session Title:
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic
Cancers Day/Time: Monday, June 3, from 1:30 - 4:30 PM
CDT Abstract: #TPS8124 Poster Bd: #381b
About RS Oncology RS Oncology is a private,
clinical-stage biopharmaceutical company leading scientific
discoveries and global collaborations to improve the lives of
patients with the aggressive cancers. Visit www.RSOncology.com or
follow us on LinkedIn and X.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240501350515/en/
Corporate Inquiries: Jarrett Duncan, CEO, RS
Oncology j.duncan@rsoncology.com